This graphing tool allows users to explore trends in workplace-sponsored health insurance premiums and worker contributions over time for different categories of employers based on results from the annual Employer Health Benefits Survey. Breakouts are…
KFF has conducted this annual survey since 1999. The archives include surveys conducted in partnership with the Health Research and Education Trust through 2017 and a small business supplement of the 1998 survey conducted by KFF. The survey was previou…
This chart collection draws on recent KFF poll findings to provide an in-depth look at the public’s attitudes toward prescription drugs and their prices. Results include Americans’ opinions on drug affordability, pharmaceutical companies, and various p…
A new KFF brief analyzes how the accessibility and cost of COVID-19 vaccines, treatments, and tests will change after the current government supply is depleted and the public health emergency ends. The Biden Administration has announced that it will ha…
A new KFF brief analyzes how the accessibility and cost of COVID-19 vaccines, treatments, and tests will change after the current government supply is depleted and the public health emergency ends. The Biden Administration has announced that it will ha…
With the depletion of the federal-purchased supply of COVID-19 vaccines, treatments and tests and end to the public health emergency on the horizon, this document provides an overview of the implications of these changes for access to these products by…
With the depletion of the federal-purchased supply of COVID-19 vaccines, treatments and tests following the end of the public health emergency, this resource provides an overview of the implications of these changes for access to people covered by Medi…
This slideshow explains the prescription drug provisions proposed in the Inflation Reduction Act as passed by the Senate
In this column for the JAMA Forum, KFF’s Larry Levitt explores the Medicare drug-price negotiation provisions and other significant drug-price changes in the Inflation Reduction Act and their potential to lead to further efforts to address health care …
In this column for the JAMA Forum, KFF’s Larry Levitt explores the Medicare drug-price negotiation provisions and other significant drug-price changes in the Inflation Reduction Act and their potential to lead to further efforts to address health care …
